Spinnovation launches biologics analysis division

Published: 8-Apr-2011
Finance Analysis Pharmaceutical

Spinnovation Biologics to provide profiling and characterisation of biologics

Spinnovation Analytical, a Dutch contract research organisation, has launched a new division called Spinnovation Biologics, which will provide spent culture media analysis and profiling and characterisation of biologics and biosimilar drugs.

Frederic Girard, chief executive of the Nijmegen-based nuclear magnetic resonance spectroscopy (NMR) specialist, said spent media analysis with Spedia-NMR would be the new company’s core service.

‘Spedia-NMR is unique and can deliver a step-fold increase in throughput and detail over standard methods, in as few as five working days,’ he said.

Spinnovation Biologics will also offer process and product bioanalysis, enabling clients to benefit from advanced insights into cell culture to enhance productivity, scalability, and reliability for QA/QC control, cGMP production and support Quality by Design.

In addition to Spedia-NMR technology, Spinnovation Biologics has a broad spectrum of analysis methods in house, including: LC-MS, LC-NMR, LC-SPE-NMR and LC-SPE-NMR-MS.

See more

You may also like

Research & Development

Pivot Park and Spinnovation Analytical join forces

Read more
To provide analytical solutions at Pivot Park Life Sciences Community, Oss, the Netherlands

Trending Articles

Upcoming event

Cleanroom Technology Awards 2026

13 April | Virtual See all

You may also like

Research & Development

Pivot Park and Spinnovation Analytical join forces

To provide analytical solutions at Pivot Park Life Sciences Community, Oss, the Netherlands
Analysis

Spinnovation Biologics predicts bioproduction performance

With the launch of Spedia-Predict
Pharmaceutical

Spinnovation introduces approach to improve biologicals manufacturing processes

Spinnovation technology delivers optimal cell viability and density, with the right safety and quality parameters in a short time frame
Analysis

Spinnovation Biologics offers service choices to meet individual analysis needs for bioprocess optimisation

Unique mix of services delivers essential support for the development and manufacture of biologics
Finance

Merck to acquire cancer biotech Terns Pharmaceuticals for $6.7bn

The purchase is the third multibillion-dollar acquisition for the pharma giant in the past year, as it moves to bolster its cancer portfolio ahead of its best-selling drug Keytruda losing patent protection in 2028
Marketing

Indena to highlight expanded HPAPI, ADC and peptide drug conjugate capabilities at DCAT Week 2026

Italian CDMO Indena will showcase its high-potency API manufacturing expertise and growing oncology-focused capabilities at DCAT Week in New York, including ten commercial HPAPIs in production and advancing work in antibody-drug and peptide drug conjugates
Manufacturing

Wilmington PharmaTech invests $50m into US small-molecule API manufacturing plant

The CRDMO will more than double the capacity in its current API reactor in Delaware, positioning itself to meet growing demand for US-based manufacturing
Subscribe now